Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Oct;38(10):1788-97.
doi: 10.1007/s00259-011-1833-x. Epub 2011 May 7.

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Jolanta Kunikowska  1 , Leszek Królicki, Alicja Hubalewska-Dydejczyk, Renata Mikołajczak, Anna Sowa-Staszczak, Dariusz Pawlak
Affiliations
Clinical Trial

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Jolanta Kunikowska et al. Eur J Nucl Med Mol Imaging. 2011 Oct.

Abstract

Purpose: Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination treatment using the high-energy 90Y beta emitter for larger lesions and the lower energy 177Lu for smaller lesions has been postulated in the literature.The aim of the study was to evaluate combined 90Y/177Lu-DOTATATE therapy in comparison to 90Y-DOTATATE alone.

Methods: Fifty patients with disseminated NET were included in the study prospectively and divided into two groups: group A (n=25) was treated with 90Y-DOTATATE, whereas group B (n=25) received the 1:1 90Y/177Lu-DOTATATE. The administered activity was based on 3.7 GBq/m2 body surface area in three to five cycles, with amino acid infusion for nephroprotection.

Results: The median overall survival time in group A was 26.2 months while in group B median survival was not reached. Overall survival was significantly higher in group B (p=0.027). Median event-free survival time in group A was 21.4 months and in group B 29.4 months (p>0.1). At the 12-month follow-up, comparison of group A vs group B showed stable disease (SD) in 13 vs 16 patients, disease regression (RD) in 5 vs 3 patients and disease progression (PD) in 3 vs 4 patients; 4 and 2 patients died, respectively. The 24-month follow-up results were SD in nine vs ten patients, RD in one patient vs none and PD in four patients in both groups; three and four patients died, respectively. Side effects were rare and mild.

Conclusion: The results indicate that therapy with tandem radioisotopes (90Y/177Lu-DOTATATE) provides longer overall survival than with a single radioisotope (90Y-DOTATATE) and the safety of both methods is comparable.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A 58-year-old man with multiple liver and peritoneum metastases of gastrinoma. a SRS with 99mTc-HYNIC-TATE before treatment with uptake in metastatic lesions in liver and peritoneum. b 24-h post-therapeutic image after administration of 90Y-DOTATATE using bremsstrahlung
Fig. 2
Fig. 2
A 42-year-old man with multiple bone metastases of atypical bronchial carcinoid tumour without hormonal activity. a SRS with 99mTc-HYNIC-TATE before treatment with uptake in metastatic lesions in bone. b 24-h post-therapeutic image after administration of 90Y/177Lu-DOTATATE using 177Lu photopeak
Fig. 3
Fig. 3
Kaplan-Meier estimators of OS
Fig. 4
Fig. 4
Kaplan-Meier estimators of EFS
Fig. 5
Fig. 5
Comparison of the PRRT results (SD, RD, PD and patients who died): a 12 months, b 24 months, c 36 months follow-up
Fig. 6
Fig. 6
Changes on CT in the size of the biggest tumours 3–6 months after completed therapy. The line represents median reduction of tumour size in % for both groups
Fig. 7
Fig. 7
Correlation between tumour size and type of therapy before and 3–6 months after therapy
Fig. 8
Fig. 8
A 62-year-old woman with multiple bone and liver metastases of pancreas neuroendocrine carcinoma without hormonal activity. a SRS with 99mTc-HYNIC-TATE before treatment with uptake in metastatic lesions in bone and liver. b 12-month follow-up shows reduced number of metastases, with only a few visible in bone. c 24-month follow-up shows nearly complete response to treatment
See this image and copyright information in PMC

Comment in

References

    1. Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, et al. ENETS Consensus Guidelines for Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology. 2009;90:214–219. doi: 10.1159/000225950. - DOI - PubMed
    1. Dharmsathaphorn K, Sherwin RS, Cataland S, Jaffe B, Dobbins J. Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med. 1980;92:68–69. - PubMed
    1. Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci. 1989;34(Suppl 3):14S–27S. doi: 10.1007/BF01536042. - DOI - PubMed
    1. Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients wit metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663. doi: 10.1200/JCO.2009.22.8510. - DOI - PubMed
    1. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704–1713. - PubMed

Publication types

MeSH terms